Biosimilars
Regulatory
Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment
Shots: The approval is based on the non-inferiority data demonstrating its biosimilarity in terms of PK, immunogenicity and safety meeting all 1Eps & results of ADACCESS study confirming its safety & efficacy with referred biologic Hymiroz’s (a TNFi) approval is third FDA approval for Sandoz which is indicated to treat RA, JIA in patients ≥4 […]Read More
